PCN27 INCONGRUENT DEFINITIONS OF RISK AND UNCERTAINTY AMONG CLINICAL ONCOLOGISTS AND ITS IMPLICATIONS FOR DECISION MAKING  by Molnar, R et al.
352 Abstracts
cost-effective became 0.96. CONCLUSION: The ability to incor-
porate prior information makes Bayesian regression a useful
method in postmarketing surveillance. Our analytical framework
can be further expanded to address selection issues.
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OBJECTIVES: The purpose of this study was to examine the
meaning given to a number of concepts of risk and uncertainty
by clinical oncologists and to better understand how physicians
use these terms in their day to day practice. METHODS: Open
ended semi-structural interviews were used to elicit deﬁnitions of
“Risk,” “Uncertainty,” and “Ambiguity,” as well as the methods
used to express the concepts and the barriers that exist in com-
municating these concepts. Participants included board regis-
tered practicing oncologists at two major academic teaching
hospitals. Purposive sampling was used to obtain a range of spe-
cialties and levels of seniority within the target population, with
a total of 14 interviews being conducted. RESULTS: A broad
range of meanings were associated with these three concepts,
with little consistency, if any, in the actual deﬁnitions given to
the key concepts. Methods for communicating risks also varied,
but all respondents found signiﬁcant barriers to communicating
these concepts with patients. A number of other key themes
emerged relating to risk and certainty, including the differences
between population and individual risk, issues of sample size and
power, and the importance of conditioning risk to the individual
patient. CONCLUSION: This paper demonstrates that there is
not a set of clear cut deﬁnitions to cover issues of risk and uncer-
tainty and that this leads to difﬁculties in interpretation and com-
munication, even among physicians and especially to patients.
There is a need for a common language to express concepts of
risk and uncertainty.
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OBJECTIVE: Risk factors for Type-2 diabetes have been associ-
ated with other conditions, including cardiovascular conditions
categorized under the metabolic syndrome. The objective of this
study was to describe the prevalence of co-morbid conditions, as
well as concomitant medication use, for Type-2 diabetes patients
in a state Medicaid population. METHODS: Data for Type-2
diabetes patients were extracted from medical claims for the year
2001 using ICD-9 codes 250.0¥–250.9¥, where x equals zero or
two. Patients under managed care coverage, or over age 65, were
excluded. The patients were followed for one-year from the
index date to determine the presence of co-morbid conditions
and prescription drug utilization. The presence of co-morbid
conditions such as cardiovascular, peripheral vascular, cere-
brovascular, complications of uncontrolled diabetes (retinopathy,
neuropathy, nephropathy), and other conditions (liver disease,
HIV, cancer) were identiﬁed using appropriate ICD-9 codes.
Drug utilization was ascertained from prescription claims data
using National Drug Classiﬁcation (NDC) codes. Prevalence 
of co-morbid conditions and concomitant medication use was
described for the overall population and on the basis of age and
gender. RESULTS: The most prevalent (70%) co-morbid condi-
tion among Type-2 diabetes patients was hypertension. In addi-
tion, approximately 55% of patients had medical services claims
for co-morbid hyperlipidemia, and 41% had co-morbid cardio-
vascular conditions. Prevalence of hypertension and cardiovas-
cular conditions among genders was similar; patients in the over
55 age category had the highest prevalence of cardiovascular
conditions (52.2%) and hypertension (76.7%). For prescription
use, nearly three-fourths of patients ﬁlled prescriptions for anti-
hypertensives; 47.1% ﬁlled prescriptions for statins, ﬁbrates, and
other lipid-lowering drugs. CONCLUSIONS: As expected from
results of studies in other Medicaid populations, hypertension
was the most prevalent co-morbid condition with Type-2 dia-
betes. Other cardiovascular conditions also prevailed, warrant-
ing treatment of these conditions as part of the metabolic
syndrome.
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OBJECTIVE: To examine the relationship between pre-existing
depression and incidence of type-2 diabetes. METHODS:
Administrative claims data of a state Medicaid were used to meet
the study objective. Medicaid enrollees with depression were
identiﬁed in the year 1997 using ICD-9 codes for depression. A
comparison group without depression was also identiﬁed in
1997. Enrollees with a medical/pharmacy claim for type-2 dia-
betes in 1997 were excluded from the analysis. Both these groups
were then followed till December 31, 2002 to identify incident
cases of type-2 diabetes. The analysis was restricted to patients
who were continuously Medicaid eligible through the period
1997–2002. In addition to univariate chi-square analysis, logis-
tic regression analysis was conducted to examine the association
between depression and incidence of type-2 diabetes controlling
for the effect of demographics and presence of co-morbidities.
RESULTS: A total of 4472 eligible enrollees with depression
were identiﬁed in the year 1997. The comparison group con-
sisted of 5195 eligible non-depressed enrollees. A signiﬁcantly
higher fraction of depressed enrollees (15.7%) developed type-2
diabetes as compared to non-depressed enrollees (11.7%) (p <
0.01). Results of the logistic regression demonstrated a signiﬁ-
cant interaction effect between gender and presence of pre-
existing depression, suggesting that the odds of developing 
incident type-2 diabetes in enrollees with depression were sig-
niﬁcant only in females. Females with pre-existing depression
were nearly one and a half times more likely to develop incident
type-2 diabetes as compared to non-depressed females, after con-
trolling for age, race, and cardiovascular co-morbidity at base-
line (Odds Ratio = 1.479; p < 0.01). CONCLUSION: The
observed higher risk of type-2 diabetes among females with
depression may suggest that physicians need to monitor diabetic
metabolic changes in females with depression for early detection
and treatment of type-2 diabetes.
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